Check out this review to access a comprehensive and up-to-date overview of the different detection platforms and therapeutic options currently available for the clinical management of advanced #EGFR -positive #NSCLC .

👇Link to the content below👇🔗sciencedirect.com/science/articl…

Directly from the 'Video Path in the Virtual Laboratory' Workshop, where participants had the opportunity to put their acquired knowledge into practice in real time, living an educational and practical experience navigating in our #Virtual Lab.
#pathology4oncology
👇Link below👇

In the ALINA phase 3 trial of adjuvant treatment for patients with resected ALK-positive non–small-cell lung cancer, disease-free survival at 2 years was 93.6% with the ALK inhibitor alectinib and 63.7% with standard chemotherapy. Full trial results: nej.md/3VUzf3M

Insights into the latest ASCO NSCLC Living Guidelines available JCO Oncology Practice from Dr. Dwight Owen et al, addressing some common questions and providing helpful decision trees for personalizing systemic therapy for patients with NSCLC.

ascopubs.org/doi/10.1200/OP…

Proud to be part of it

Biomarkers Atlas an invaluable resource for clinical practice and real-world research. Kudos to the incredible effort in bringing together an outstanding Italian collaborative group!

Umberto Malapelle Francesco Maria Lucia Reale and Silvia Novello

lungcancerjournal.info/article/S0169-…

An audit of the biomarkers ATLAS project (biomarkersatlas.com) is available Lung Cancer Journal. A knowledge-based database integrating clinical and molecular records from 80 referral Italian institutions led by Dr. Umberto Malapelle.

lungcancerjournal.info/article/S0169-…

Most viewed in the last 7 days from JAMA Oncology:

Do patients with resectable NSCLC and tumor programmed cell death 1 ligand 1 levels less than 1% benefit from neoadjuvant chemoimmunotherapy?

ja.ma/3TELLl3

Don't miss this essential read! 📖 Pasi Jänne & colleagues Dana-Farber delve into a crucial topic: #LungCancer in non-smokers. Published in NatureRevClinOncol, it's a must-read
#LCSM . Check it out!
nature.com/articles/s4157…

#ELCC24 Real world data on #MET exon 14 mutant NSCLC from the Italian ATLAS database by Dr. Maria Lucia Reale et al - RR to TKIs (capmatinib and tepotinib) was 46% as 1L and 33% in later lines with mPFS 6.6m and mOS 10.7m. Also noted 41% intracranial response. IASLC ESMO - Eur. Oncology

METex14 NSCLC: real world data from the Italian biomarker ATLAS database Biomarkers Atlas at #ELCC2024 . Proud to be part of this group of colleagues and friends Francesco Giulia pasello Marcello Tiseo Umberto Malapelle

📢 See you tomorrow 12.00-12.45 PM at poster display section to discuss our poster 'Germline testing in NSCLC: Real-world impact of the discovery of Pathogenic Germline Variants in the INHERITY LC study'
#ELCC24 ICAPEM ESMO - Eur. Oncology

Tumore uroteliale metastatico: enfortumab vedotin e pembrolizumab rivoluzionano il trattamento di prima linea tinyurl.com/29n6uc4k

In the last years, careful attention has been paid on  #KRAS  and  #NRAS  gene mutations in #NSCLC and #CRC patients because of their prognostic and predictive roles.
Get more information by reading this Biomarkers Atlas paper published on ScienceDirect.
🔗sciencedirect.com/science/articl…

An elegantly written commentary by Umberto Malapelle and Silvia Novello on The Lancet Europe: Biomarker testing in patients with advanced non-small cell lung cancer: the never-ending story !

sciencedirect.com/science/articl…

Come da tradizione, WALCE partecipa alla #Justthewomaniam
Passate a trovarci oggi e domani allo Stand in piazza San Carlo a #Torino

JTWIA

Il ministro dell'Istruzione e del Merito, Giuseppe Valditara, sta valutando di introdurre dal prossimo anno scolastico il giudizio 'gravemente insufficiente' nelle scuole elementari. Ecco, signor Ministro, non lo faccia. Lasci stare. Introduca piuttosto insegnanti di sostegno, e…

Phase II results of glesatinib (MGCD265) in #MET NSCLC Lung Cancer Journal. Overall RR 11.8%, mPFS 4m, mOS 7m. RR 10.7% in METex14 by tissue (n=28), RR 25% METex14 by ctDNA (n=8), RR 15% MET amp by tissue. Diarrhea in 82%, nausea 50%. Study terminated early.

lungcancerjournal.info/article/S0169-…

Press release: phase III LAURA trial meets primary endpoint. Stage III #EGFR NSCLC post chemoradiation, indefinite osimertinib superior to placebo. No surprise - eager to see magnitude of benefit, patterns of relapse, OS trends, and crossover rate…

astrazeneca.com/media-centre/p…

Rechallenge risk after ILD with osimertinib in #JTOCRR . Retrospective study of 913 pts with #EGFR NSCLC receiving osimertinib: 35 had ILD (8 fatal cases). 8 pts rechallenged with osi and 5/8 had ILD (3 fatal). 9 pts given erlotinib and 1 had ILD.

jtocrr.org/article/S2666-…